Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Saved in:

Bibliographic Details
Main Authors:	Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-01-01
Series:	Dermatology and Therapy
Online Access:	https://doi.org/10.1007/s13555-024-01328-4
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet